CA-ARCULES
11.2.2020 17:32:06 CET | Business Wire | Press release
Arcules , leading innovators in integrated video and access control cloud services, today announced the commercial availability of the Arcules-XProtect Hybrid™ VMS Solution in North America and Europe. The solution represents a combination of the Arcules Video Surveillance as a Service (VSaaS) integrated with Milestone XProtect Corporate on-premise video management software (VMS). The result is a flexible and feature-rich hybrid video surveillance solution ideal for organizations looking to centralize their dispersed video surveillance operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005274/en/
With Arcules-XProtect Hybrid VMS Solution, Milestone XProtect customers can deploy remote sites quickly, with minimal IT resources and downtime while still benefiting from the strong capabilities of XProtect on-premise VMS. Additionally, Arcules’ intuitive platform provides sites and cameras connected to Arcules VSaaS an underlying cloud infrastructure such as compatibility between sites, low video latency, data encryption, redundancy, streamlined maintenance with automatic updates, and easy onboarding.
“Milestone resellers and end customers are planning their deployment to take advantage of the many benefits of cloud computing. This integration gives Milestone XProtect Corporate customers a new hybrid cloud computing deployment option,” said Bjørn Skou Eilertsen, CTO of Milestone Systems. “The typical Milestone XProtect Corporate user has many branch offices of different sizes and locations. Enabling this hybrid deployment option can allow them to simplify large scale deployments. After the Arcules system is Interconnected the user can utilize these Arcules connected cameras with the advanced XProtect Corporate product capabilities.”
The Arcules-XProtect Hybrid VMS Solution uses Milestone Interconnect™ technology to combine the hyper-scalability and licensing flexibility of Arcules cloud service with the feature-rich video management functions of XProtect Corporate. The combination of these advanced technologies provides uniform access to live video, recordings and alarms across cameras physically connected on-premise and virtually connected via the Arcules cloud, through XProtect Smart Client, XProtect Smart Wall, and the web and mobile clients.
Organizations with distributed locations such as healthcare, retail, corporate campuses and education, and utility environments all benefit from high-performance cloud services to provide real-time insight in the event of an incident in remote areas. The Arcules-XProtect Hybrid VMS Solution also adds value to monitoring stations and law enforcement organizations that use XProtect Corporate as their VMS platform. Such organizations can now access cameras and customers subscribed to the Arcules cloud service directly from their on-premise XProtect system.
“The Arcules-XProtect Hybrid VMS Solution is an ideal solution for businesses looking to expand their surveillance operation across geographically dispersed locations,” said Arcules CEO Andreas Pettersson. “These businesses can enjoy the strong capabilities of on-premise VMS while reducing their capital investment. The solution also enables organizations to better manage their operational costs as a result of flexible pricing schemes and minimal hardware requirements.”
The Arcules-XProtect Hybrid VMS Solution regional availability outside of North America and Europe is based on market demand conditioned by datacenter availability and/or the possibility to utilize data centers in other regions.
Arcules will demonstrate the solution in booth #809 at the MIPS 2020 Conference , February 17-19, at the Gaylord Texan in Grapevine, TX as well as in Arcules booth #31081 and Milestone booth #18053 during the 2020 ISC West Conference and Expo , March 17-20, at the Sands Expo in Las Vegas.
About Arcules
Arcules, a Canon Group company, addresses the unmet need of modern enterprises for integrated cloud-based video surveillance, access control and analytics. Using the latest developments in cloud, artificial intelligence and machine learning, Arcules combines previously untapped video monitoring data with sensor data and analytics to deliver actionable insights that ultimately drive better business decisions, optimize operations and improve safety. Arcules is headquartered in Irvine, Calif. Visit www.arcules.com for more information and follow us on LinkedIn , Facebook , and Twitter .
About Milestone Systems
Milestone Systems is a leading provider of open platform video management software; technology that helps the world see how to ensure safety, protect assets and increase business efficiency. Milestone enables an open platform community that drives collaboration and innovation in the development and use of network video technology, with reliable and scalable solutions that are proven in more than 500,000 installations worldwide. Founded in 1998, Milestone is a stand-alone company in the Canon Group. For more information visit: http://www.milestonesys.com . For news and other press releases, visit our Newsroom . Click here for information on Trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005274/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom